Search the site
Regulatory Law
We assist our clients on regulatory issues facing pharmaceutical and food and beverage companies. We advise our clients on matters under the Food and Drugs Act, Food and Drugs Regulations, freedom of information acts, OPML, and other regulatory matters before Health Canada, Canadian Food Inspection Agency, provincial formularies, and Canada Customs.
The Team
Regulatory Law
Recent Cases
Regulatory Law
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,652,442 and 2,771,403 (lenvatinib).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,632,375 (diclofenac).
Section 45 proceedings before the Trademarks Office regarding the trademark CHICO owned by Bedessee Imports Ltd. Result: Registration maintained for all of the goods in the registration.
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,932,603 (diclofenac).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,861,480 (trifluridine/tipiracil hydrochloride).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,861,480; 2,914,999 and 2,985,006 (trifluridine/tipiracil).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,606,282, 2,967,453, and 3,003,988 (dolutegravir-abacavir-lamivudine).
Counsel to defendants in patent infringement action relating to use of imazamox herbicides regarding Patent No. 2,447,445.
Counsel to respondent trademark owner in expungement proceedings regarding trademark TMA822855. Successfully applied for dismissal of proceeding due to undue and inexcusable delay (2024 FC 579).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,606,282 (dolutegravir).
Counsel to defendants in trademark infringement and passing off action relating to agricultural products regarding trademark TMA483211. Settled on favourable terms.
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,534,024 (canagliflozin).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,671,357 (canagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,655,212 and 2,705,163 (vortioxetine).
Counsel to defendants in patent infringement action relating to laminate flooring regarding Patent Nos. 2,522,321, 2,226,286, 2,410,206, and 2,475,076.
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,851,588 (brexpiprazole).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,602,247 (brexpiprazole).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,832,157 (brexpiprazole).
This was an appeal of a decision on a motion to strike certain portions of Bell Canada's Statement of Defence and Counterclaim. Initially the case management judge struck portions of Bell Canada's claims against our clients, the Plaintiffs/Defendants by Counterclaim and Aird & Berlis. That decision was appealed by Bell Canada. The Federal Court judge dismissed the appeal and determined that the case management judge was correct in dismissing certain claims against the Plaintiffs/Defendants by Counterclaim and Aird & Berlis including claims related to alleged misuse of copyright and unlawful means conspiracy.
Counsel to the opponent in trademark opposition relating to industrial equipment. Successfully opposed registration of mark (2023 TMOB 64).
Counsel to trademark owner in expungement proceedings. Successfully maintained marks (2023 TMOB 43; 2023 TMOB 44; 2023 TMOB 45).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,496,249 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,557,801, 2,606,650, 2,751,833 and 2,813,661 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,738,367 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,696,558 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,782,179 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,472,399, 2,590,511 and 2,703,598 (sacubitril/valsartan)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,732,803 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,649,922 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,696,558 and 2,752,435 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,936,852, 2,485,143, 2,544,621 and 2,781,799 (riociguat)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,752,437 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,845,553 (tenofovir alafenamide).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,845,553 and 2,990,210 (tenofovir alafenamide/emtricitabine).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,589,765, 2,589,921, 2,701,778, 2,741,312 and 2,873,044 (carfilzomib).
Motion to strike portions of the Amended Statement of Defence and Counterclaim w.r.t. ss. 41.25 and 41.26 of the Copyright Act.
Actions under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,450,740, No. 2,529,400 and No. 2,536,251 as well as patent infringement actions relating to Patent No. 2,518,435 with respect to products containing sitagliptin and products containing both sitagliptin and metformin.
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,682,598 with respect to products containing sapropterin.
Action for copyright infringement. Acting as counsel on motions relating to the Statement of Claim and appeals therefrom.
Trademark expungement case regarding Registration Nos. TMA617,580 and TMA638,321 (TUSCANI)
Counsel to the defendants in patent infringement action relating to control system for lift axles on vehicles regarding Patent No. 2,756,470. Settled shortly before trial on favourable terms.
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent Nos. 2,440,472, 2,521,885, and 2,803,922 (doxycycline)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent Nos. 2,621,273 and 2,659,770 (macitentan)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,402,894 (saxagliptin)
Application for leave to appeal to the Supreme Court of Canada in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,752,550 (pomalidomide)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,794,060 (pomalidomide)
Trademark expungement case regarding Registration No. TMA381,146 (LIMCA)
Counsel to defendants in copyright infringement proceeding. Proceeding dismissed (2019 FC 1199).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,791,171 (apixaban)
Appeal of a trademark expungement case regarding Registration Nos. TMDA22577 and UCA44562 (HORLICKS)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,461,202 (apixaban)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,344,318 and 2,743,326 (daptomycin)
Patent infringement regarding Patent No. 2,743,326 (daptomycin)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,762,013 and 2,620,380 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,709,997 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,620,380 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,667,654 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,937,365 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,631,646 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,014 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,358 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,819,967 (pirfenidone)
Interlocutory appeal in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)
Trademark opposition case regarding Registration No. 1,691,811 (INSTA-LOC)
Counsel to appellant in appeal of judgment of patent infringement. Successful on appeal and matter remitted to trial judge for re-determination in accordance with appeal reasons (2018 FCA 140). Matter subsequently settled.
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,507,002 and 2,496,780 (silodosin)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,823,159, 2,634,310 and 2,547,113 (rivaroxaban)
Motion/Application under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab)
Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), TMA157,162 (ENERGIZER) and TMA740,338 (ENERGIZER)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab)
Statutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)
Appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)
Trademark infringement action against the owner of a s. 9 mark
CIRA domain name dispute relating to the domain name STRIPMEISTER.CA
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,823,159, 2,634,310 and 2,547,113 (rivaroxaban)
Trademark expungement regarding Registration Nos. TMDA22577 and UCA44562 (HORLICKS)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,477,301, 2,688,709, 2,476,983, 2,688,694, 2,537,092, 2,687,927, 2,688,695, 2,741,575, 2,688,708, 2,687,924 and 2,741,412 (lenalidomide)
Trademark expungement regarding Registration No. TMA400474 (RED BARN)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,415,403 (acetaminophen)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,705,733 (acetaminophen)
Patent infringement case regarding Patent No. 2,407,556 (trastuzumab)
Patent impeachment case regarding Patent No. 2,540,547 (trastuzumab)
Patent impeachment case regarding Patent No. 2,329,829 (trastuzumab)
Patent impeachment case regarding Patent No. 2,376,596 (trastuzumab)
Patent infringement case regarding Patent No. 2,787,952 (bevacizumab) with counterclaim for infringement under the new Patented Medicines (Notice of Compliance) Regulations
Patent impeachment case regarding Patent No. 2,596,133 (trastuzumab)
Interlocutory decision in a trademark infringement action
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,366,785 and 2,476,934 (etanercept)
Appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Application under s. 18.1 of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,586,023 (sevelamer)
Patent infringement case regarding Patent Nos. 2,475,076 and 2,522,321 (Hard Wood Floor Panels and Manufacturing)
Contact us.
